Incyte (INCY) and Eli Lilly (LLY): The New England Journal of Medicine published detailed results of RA-BEACON — a pivotal phase 3 global study of baricitinib, a once-daily oral treatment for moderate-to-severe rheumatoid arthritis (RA).

The study met its primary endpoint of ACR 20 response for baricitinib compared with placebo at week 12.

ACR 20 response rates were (P≤0.001 for each baricitinib dose versus placebo):

55 percent for baricitinib 4 mg; 49 percent for baricitinib 2 mg; 27 percent for placebo